Keros Therapeutics (KROS) Price & Analysis

Compare

348 Followers

KROS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$9.12 - $72.37

Previous CloseN/A

Volume109.28K

Average Volume (3M)482.26K

Market Cap

$605.58M

Enterprise Value-$130.08M

Total Cash (Recent Filing)$690.22M

Total Debt (Recent Filing)$17.95M

Price to Earnings (P/E)49.5

Beta0.83

Next Earnings

Oct 30, 2025

EPS Estimate

-1.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding40,615,414

10 Day Avg. Volume545,673

30 Day Avg. Volume482,256

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.21

Enterprise Value/Revenue-0.56

Enterprise Value/Gross Profit-0.56

Enterprise Value/Ebitda-5.19

Forecast

1Y Price Target

$23.29

Price Target Upside50.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Clinical DataThe preclinical and early clinical data show promising activity across multiple DMD-relevant pathways including muscle regeneration, bone health, fibrosis reversal, and fat mass reduction.

Clinical DevelopmentKeros has officially narrowed its focus to a single internal clinical program: KER-065 for Duchenne muscular dystrophy (DMD).

Financial PositionWith $690M in cash and a planned $375M return of capital, Keros retains significant operational runway through 1H28.

Bears Say

Clinical UncertaintyA dose-dependent hemoglobin increase creates uncertainties in the safety profile.

Program DiscontinuationThe discontinuation of cibotercept following an unfavorable safety profile in PAH removes a previous value driver.

Valuation ConcernsThe addition of the program into valuation continues to appear premature as many details of the Ph2 study remain to be finalized.

Keros Therapeutics News

ADAR1 Capital sends letter to Keros Therapeutics urging board changes

ADAR1 Capital Management, the largest stockholder of Keros Therapeutics (KROS), with approximately 13.3% of the company’s outstanding shares,...

8d ago

KROS

Keros Therapeutics granted Orphan Drug designation for KER-065 in DMD

Keros Therapeutics (KROS) announced the U.S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the...

9d ago

KROS

Keros Therapeutics’ treatment of Duchenne MD granted FDA orphan designation

Keros Therapeutics (KROS)’ treatment of Duchenne muscular dystrophy was granted FDA orphan designation, according to a post to...

10d ago

KROS

Keros Therapeutics to discontinue cibotercept, announces COO departure

Keros Therapeutics (KROS) announced a strategic realignment designed to reallocate resources towards the development of its key clinical...

22d ago

KROS

Keros Therapeutics reports Q2 EPS (76c), consensus ($1.13)

Reports Q2 revenue $18.17M, consensus $4.21M. “The second quarter marked an important point for Keros, as Keros’ Board...

22d ago

KROS

Keros Therapeutics CEO to Speak at Healthcare Conferences

An update from Keros Therapeutics ( ($KROS) ) is now available. On August 28, 2025, Keros Therapeutics announced...

11h ago

KROS

Keros Therapeutics Gains FDA Orphan Drug Designation

Keros Therapeutics ( ($KROS) ) just unveiled an announcement. On August 20, 2025, Keros Therapeutics announced that the...

9d ago

KROS

Keros Therapeutics Reports Strong Revenue Growth

Keros Therapeutics, Inc. ( ($KROS) ) has released its Q2 earnings. Here is a breakdown of the information...

15d ago

KROS

Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics

Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Keros Therapeutics. The associated price target...

21d ago

KROS

Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks

Keros Therapeutics, Inc. (KROS) has disclosed a new risk, in the Corporate Activity and Growth category. Keros Therapeutics,...

21d ago

KROS

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments

In a report released today, Yun Zhong from Wedbush maintained a Hold rating on Keros Therapeutics, with a...

22d ago

KROS

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Prudent Resource Allocation

TD Cowen analyst Tyler Van Buren has maintained their neutral stance on KROS stock, giving a Hold rating...

22d ago

KROS

Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating

William Blair analyst Matt Phipps has maintained their neutral stance on KROS stock, giving a Hold rating on...

22d ago

KROS

Keros Therapeutics Announces Strategic Realignment and Leadership Changes

Keros Therapeutics ( ($KROS) ) just unveiled an announcement. On August 6, 2025, Keros Therapeutics announced a strategic...

22d ago

KROS

KROS FAQ

What was Keros Therapeutics’s price range in the past 12 months?

Keros Therapeutics lowest stock price was $9.12 and its highest was $72.37 in the past 12 months.

What is Keros Therapeutics’s market cap?

Keros Therapeutics’s market cap is $605.58M.

When is Keros Therapeutics’s upcoming earnings report date?

Keros Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 62 days.

How were Keros Therapeutics’s earnings last quarter?

Keros Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$1.11 by $0.35.

Is Keros Therapeutics overvalued?

According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Keros Therapeutics pay dividends?

Keros Therapeutics does not currently pay dividends.

What is Keros Therapeutics’s EPS estimate?

Keros Therapeutics’s EPS estimate is -1.02.

How many shares outstanding does Keros Therapeutics have?

Keros Therapeutics has 40,615,414 shares outstanding.

What happened to Keros Therapeutics’s price movement after its last earnings report?

Keros Therapeutics reported an EPS of -$0.76 in its last earnings report, beating expectations of -$1.11. Following the earnings report the stock price went down -7.287%.

Which hedge fund is a major shareholder of Keros Therapeutics?

Currently, no hedge funds are holding shares in KROS

Keros Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

3.33%

Trailing 12-Months

Asset Growth

66.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Keros Therapeutics

Keros Therapeutics, Inc. (KROS) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's primary focus is on developing therapies that target the transforming growth factor-beta (TGF-β) family of proteins, which are implicated in various diseases. Keros Therapeutics' core products aim to treat conditions such as anemia, thrombocytopenia, and bone diseases by modulating these protein pathways to improve patient outcomes.

Keros Therapeutics (KROS) Earnings & Revenues

Historic Earnings Reports

KROS Stock 12 Month Forecast

Average Price Target

$23.29

▲(50.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","21":"$21","34":"$34","47":"$47","60":"$60"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,21,34,47,60],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,15.910769230769231,17.501538461538463,19.092307692307692,20.683076923076925,22.273846153846154,23.864615384615384,25.455384615384617,27.046153846153846,28.636923076923075,30.22769230769231,31.818461538461538,33.40923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,15.01,15.7,16.39,17.08,17.77,18.46,19.15,19.84,20.53,21.22,21.91,22.6,{"y":23.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.32,14.372307692307693,14.424615384615384,14.476923076923077,14.52923076923077,14.581538461538461,14.633846153846154,14.686153846153847,14.73846153846154,14.79076923076923,14.843076923076923,14.895384615384616,14.947692307692307,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.36,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.79,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >